Impaired calcium signalling and neuropsychiatric disorders in Darier disease: An exploratory review

Austin Ambur1, Asma Zaidi2, Charles Dunn1

  • 1Department of Dermatology, Kansas City University, Oviedo, Florida, USA.

Insights

Darier disease, a genetic skin disorder, is linked to significant neuropsychiatric conditions. This review explores the underlying mechanisms and potential treatments for these associated brain disorders.

Area of Science:

  • Genetics and Molecular Biology
  • Neuroscience
  • Dermatology

Background:

  • Darier disease (DD) is an autosomal dominant skin disorder stemming from mutations in the ATP2A2 gene, impacting cellular calcium regulation (SERCA2).
  • Patients with DD exhibit a high incidence of neuropsychiatric disorders, including intellectual disability, bipolar disorder, schizophrenia, and suicidality.
  • The pathophysiological links between DD and these neurological conditions remain underexplored.

Purpose of the Study:

  • To review literature on neuropsychiatric disorders associated with Darier disease.
  • To elucidate the pathophysiological mechanisms connecting DD and neurological conditions.
  • To examine potential therapeutic interventions for future development.

Main Methods:

  • A comprehensive literature search was conducted using PubMed.
  • Keywords included Darier disease, neuropsychiatric disorders, ATP2A2 gene, SERCA2, and related signaling pathways.
  • Sixty-one relevant articles published within the last 40 years were included in this review.

Main Results:

  • The review synthesizes current knowledge on the association between Darier disease and various neuropsychiatric conditions.
  • It highlights the role of impaired calcium homeostasis due to SERCA2 dysfunction in the central nervous system.
  • Potential mechanisms involving sphingosine-1-phosphate and P2X7 receptor signaling are discussed.

Conclusions:

  • Understanding the link between Darier disease genetics and neuropsychiatric conditions is crucial.
  • Further research into the shared pathophysiological pathways can guide the development of targeted therapies.
  • This review provides a foundation for investigating novel interventions for DD patients with neurological comorbidities.

Related Concept Videos

Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.6K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
695
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663